Overview

Pirfenidone Viatris is used to treat adults with mild to moderate idiopathic pulmonary fibrosis (IPF). IPF is a long-term disease in which fibrous scar tissue continuously forms in the lungs, causing persistent cough, frequent lung infections and severe shortness of breath. ‘Idiopathic’ means that the cause of the disease is unknown.

Pirfenidone Viatris is a ‘generic medicine’. This means that it contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Esbriet. For more information on generic medicines, see the question-and-answer document here.

Pirfenidone Viatris contains the active substance pirfenidone.

Pirfenidone Viatris is available as tablets (267, 534 or 801 mg) that are taken at mealtimes. The dose of Pirfenidone Viatris is increased steadily, starting with 267 mg three times a day in the first week, to 534 mg three times a day in the second week and 801 mg three times a day from the third week onwards.

Patients who have side effects such as stomach problems, skin reactions to light or significant changes in the levels of liver enzymes may need to take a lower dose or have their treatment interrupted at least temporarily.

Pirfenidone Viatris can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in the diagnosis and treatment of IPF.

For more information about using Pirfenidone Viatris, see the package leaflet or contact your doctor or pharmacist.

The mechanism of action of pirfenidone, the active substance in Pirfenidone Viatris, is not fully understood but it has been shown to reduce the production of cells and substances involved in the formation of fibrous scar tissue, thereby slowing down the progression of IPF in patients.

Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Esbriet, and do not need to be repeated for Pirfenidone Viatris. 

As for every medicine, the company provided studies on the quality of Pirfenidone Viatris. The company also carried out a study that showed that it is ‘bioequivalent’ to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

Because Pirfenidone Viatris is a generic medicine and is bioequivalent to the reference medicine, Esbriet, its benefits and risks are taken as being the same as the reference medicine’s.

The European Medicines Agency concluded that, in accordance with EU requirements, Pirfenidone Viatris has been shown to have comparable quality and to be bioequivalent to Esbriet. Therefore, the Agency’s view was that, as for Esbriet, the benefits of Pirfenidone Viatris outweigh the identified risks and it can be authorised for use in the EU.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pirfenidone Viatris have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Pirfernidone Viatris are continuously monitored. Suspected side effects reported with Pirfenidone Viatris are carefully evaluated and any necessary action taken to protect patients.

Pirfenidone Viatris received a marketing authorisation valid throughout the EU on 10 January 2023.

Pirfenidone Viatris : EPAR - Medicine overview

български (BG) (142.69 KB - PDF)
español (ES) (119.39 KB - PDF)
čeština (CS) (141 KB - PDF)
dansk (DA) (118.42 KB - PDF)
Deutsch (DE) (121.64 KB - PDF)
eesti keel (ET) (107.47 KB - PDF)
ελληνικά (EL) (143.15 KB - PDF)
français (FR) (119.77 KB - PDF)
hrvatski (HR) (137.5 KB - PDF)
italiano (IT) (117.66 KB - PDF)
latviešu valoda (LV) (149.25 KB - PDF)
lietuvių kalba (LT) (140.39 KB - PDF)
magyar (HU) (140.26 KB - PDF)
Malti (MT) (142.55 KB - PDF)
Nederlands (NL) (118.79 KB - PDF)
polski (PL) (142.85 KB - PDF)
português (PT) (119.66 KB - PDF)
română (RO) (138.57 KB - PDF)
slovenčina (SK) (140.23 KB - PDF)
slovenščina (SL) (136.86 KB - PDF)
Suomi (FI) (117.46 KB - PDF)
svenska (SV) (117.34 KB - PDF)

Pirfenidone Viatris : EPAR - Risk Management Plan

Product information

Pirfenidone Viatris : EPAR - Product Information

български (BG) (505.16 KB - PDF)
español (ES) (250.79 KB - PDF)
čeština (CS) (362.06 KB - PDF)
dansk (DA) (404.97 KB - PDF)
Deutsch (DE) (463.96 KB - PDF)
eesti keel (ET) (595.83 KB - PDF)
ελληνικά (EL) (542.83 KB - PDF)
français (FR) (478.13 KB - PDF)
hrvatski (HR) (472.67 KB - PDF)
íslenska (IS) (439.13 KB - PDF)
italiano (IT) (406.96 KB - PDF)
latviešu valoda (LV) (475.98 KB - PDF)
lietuvių kalba (LT) (454.55 KB - PDF)
magyar (HU) (477.06 KB - PDF)
Malti (MT) (561.65 KB - PDF)
Nederlands (NL) (446.69 KB - PDF)
norsk (NO) (397.71 KB - PDF)
polski (PL) (499.13 KB - PDF)
português (PT) (399.87 KB - PDF)
română (RO) (436 KB - PDF)
slovenčina (SK) (367.67 KB - PDF)
slovenščina (SL) (354.54 KB - PDF)
Suomi (FI) (406.3 KB - PDF)
svenska (SV) (411.92 KB - PDF)

Latest procedure affecting product information: IB/0002

20/11/2023

Globe icon

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

Pirfenidone Viatris : EPAR - All Authorised presentations

български (BG) (53.29 KB - PDF)
español (ES) (22.2 KB - PDF)
čeština (CS) (66.72 KB - PDF)
dansk (DA) (23.8 KB - PDF)
Deutsch (DE) (52.69 KB - PDF)
eesti keel (ET) (25.66 KB - PDF)
ελληνικά (EL) (52.43 KB - PDF)
français (FR) (26.08 KB - PDF)
hrvatski (HR) (68.25 KB - PDF)
íslenska (IS) (24.4 KB - PDF)
italiano (IT) (24.91 KB - PDF)
latviešu valoda (LV) (50.82 KB - PDF)
lietuvių kalba (LT) (45.85 KB - PDF)
magyar (HU) (72.58 KB - PDF)
Malti (MT) (39.37 KB - PDF)
Nederlands (NL) (24 KB - PDF)
norsk (NO) (22.19 KB - PDF)
polski (PL) (28.1 KB - PDF)
português (PT) (24.65 KB - PDF)
română (RO) (42.95 KB - PDF)
slovenčina (SK) (43.41 KB - PDF)
slovenščina (SL) (68.75 KB - PDF)
Suomi (FI) (30.85 KB - PDF)
svenska (SV) (24.42 KB - PDF)

Product details

Name of medicine
Pirfenidone Viatris
Active substance
Pirfenidone
International non-proprietary name (INN) or common name
pirfenidone
Therapeutic area (MeSH)
  • Idiopathic Pulmonary Fibrosis
  • Lung Diseases
  • Respiratory Tract Diseases
Anatomical therapeutic chemical (ATC) code
L04AX05

Pharmacotherapeutic group

Immunosuppressants

Therapeutic indication

Pirfenidone Viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF).

Authorisation details

EMA product number
EMEA/H/C/005862

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Marketing authorisation holder
Viatris Limited

Damastown Industrial Park 
Mulhuddart  
Dublin 15 
Dublin  
Ireland

Opinion adopted
10/11/2022
Marketing authorisation issued
10/01/2023
Revision
1

Assessment history

Pirfenidone Viatris : EPAR - Procedural steps taken and scientific information after authorisation

Pirfenidone Viatris : EPAR - Public assessment report

CHMP summary of positive opinion for Pirfenidone Viatris

This page was last updated on

How useful do you find this page?